BBB-Therapeutics B.V.
π³π±Netherlands
- Country
- π³π±Netherlands
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- BBB-Therapeutics B.V.
- Target Recruit Count
- 47
- Registration Number
- NCT02048358
- Locations
- π³π±
VUmc, PET and neurology clinical research unit, Amsterdam, Noord-Holland, Netherlands
π³π±Centre for Human Drug Research (CHDR), Leiden, Netherlands
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- BBB-Therapeutics B.V.
- Target Recruit Count
- 84
- Registration Number
- NCT01386580
- Locations
- π³π±
Vrije Universiteit medisch centrum (Vumc), Amsterdam, Netherlands
πΊπΈUNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
π«π·Institut Curie, Paris, Paris Cedex 05, France
Β© Copyright 2024. All Rights Reserved by MedPath